WellStar Cancer Network 2016 Annual Report
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
QUALITY METRICS<br />
i. Number of surgeries: 182<br />
ii. Percentage of Stage I, II, and III patients that are seen in STAT Clinic: 53.2%<br />
iii. Average & median number of pack years – median 40 years, average 46.97 years<br />
Surgery Not the First Course of<br />
Treatment for cN2 Lung <strong>Cancer</strong><br />
Systemic Therapy Following<br />
Surgery for Lymph Node<br />
Positive Lung Cases<br />
100<br />
100<br />
80<br />
60<br />
90.5%<br />
85%<br />
80<br />
60<br />
90%<br />
85%<br />
40<br />
40<br />
20<br />
20<br />
0<br />
<strong>WellStar</strong><br />
Benchmark<br />
0<br />
<strong>WellStar</strong><br />
Benchmark<br />
Benchmark: CP3R Expected Performance<br />
Benchmark: CP3R Expected Performance<br />
Only 20% of patients with non–small-cell lung cancer<br />
(NSCLC) present with early-stage disease, which has been<br />
traditionally treated with surgical resection alone. In patients<br />
with stage IIIA disease, the role of surgery is significantly<br />
more complicated. Patients with stage III disease are at<br />
higher risk for occult metastatic disease and local disease<br />
progression, and treatment paradigms must include<br />
therapies that provide both local and distant disease control.<br />
Adjuvant chemotherapy is the standard of care in<br />
patients with completely resected stage II and III NSCLC.<br />
Generally, the absolute OS benefit with chemotherapy at<br />
five years has been 4%–15% with the most recent metaanalyses<br />
showing a 4%–5% benefit across all stages.<br />
Source: American College of Radiology<br />
Source: American College of Radiology<br />
WELLSTAR CANCER NETWORK • <strong>2016</strong> ANNUAL REPORT • 21
Change language